Perspectives: Other ErbB2-Targeted Therapies.

SUMMARY: Despite the success of individualized targeted therapies in women with breast cancer with current available compounds, new drugs - especially with different mechanisms of resistance - are under development. A range of novel targeted agents for women with tumors that overexpress ErbB2 (HER2) and progress on trastuzumab and lapatinib have entered clinical studies. Most of these agents are monoclonal antibodies or multifunctional tyrosine kinase inhibitors. Recently published data even showed encouraging synergistic effects of several new substances, which in the future could pose as a chemotherapy-free treatment option in the metastatic setting.